Caihua Sang,Qiang Liu,Yiwei Lai,Shijun Xia,Ruhong Jiang,Songnan Li,Qi Guo,Qifan Li,Mingyang Gao,Xueyuan Guo,Lihong Huang,Nian Liu,Chenxi Jiang,Song Zuo,Xiaoxia Liu,Mengmeng Li,Weili Ge,Shangming Song,Lianghua Chen,Shuanglun Xie,Jiangang Zou,Ke Chen,Xiangfei Liu,Hesheng Hu,Xinhua Wang,Jinlin Zhang,Zhaojun Wang,Chi Wang,Liu He,Chao Jiang,Ribo Tang,Ning Zhou,Yunlong Wang,Deyong Long,Xin Du,Chenyang Jiang,Laurent Macle,Jianzeng Dong,Changsheng Ma,Wei Wang,Xin Zhao,Changyi Li,Zhuo Liang,Xu Li,Xiangyi Kong,Wenli Dai,Yufeng Wang,Lu Yu,Xueyan Ding,Hui Cheng,Jianwei Lin,Pei Zhang,Yaxun Sun,Xiaofeng Hou,Yao Wang,Yumei Xue,Rong Bai,Jing Du

Abstract:ImportanceSuccess rates of pulmonary vein isolation (PVI) are modest for persistent atrial fibrillation (AF). Additional linear ablation beyond PVI has not been proved superior to PVI alone in randomized trials. Ethanol infusion of the vein of Marshall (EIVOM) facilitates ablation at the mitral isthmus and may lead to improved effectiveness of a linear ablation strategy.ObjectiveTo determine whether linear ablation with radiofrequency energy combined with EIVOM added to PVI improves sinus rhythm maintenance compared with PVI alone in patients with persistent AF.Design, Setting, and ParticipantsThe PROMPT-AF trial is an investigator-initiated, multicenter, open-label, randomized trial involving 12 tertiary hospitals in China. A total of 498 patients aged 18 to 80 years, with AF persisting for more than 3 months, undergoing first-time AF ablation, were enrolled and randomized from August 27, 2021, to July 16, 2023.InterventionsPatients were randomized to undergo PVI alone or PVI plus EIVOM and linear ablation (intervention). The latter group first underwent EIVOM, followed by PVI and linear ablation of the left atrial roof, mitral isthmus, and cavotricuspid isthmus.Main Outcomes and MeasuresThe primary end point was freedom from any documented atrial arrhythmias lasting more than 30 seconds, without the use of antiarrhythmic drugs within 12 months. Secondary outcomes included freedom from atrial arrhythmia recurrence, AF, atrial arrhythmia recurrence after multiple procedures, and documented atrial tachycardia or atrial flutter with or without antiarrhythmic drugs; AF burden; and improvement in quality of life. Patients were monitored with wearable single-lead electrocardiographic (ECG) patches, worn for 24 hours a week, supplemented by symptom-triggered ECGs and Holter monitoring.ResultsAmong 498 randomized patients, 495 (99.4%) were included in the primary analysis (mean age, 61.1 years [SD, 9.7] years, 361 male [72.9%]). After 12 months, 174 of 246 patients (70.7%) assigned to undergo PVI plus EIVOM and linear ablation and 153 of 249 patients (61.5%) assigned to undergo PVI alone remained free from atrial arrhythmias without taking antiarrhythmic drugs (hazard ratio, 0.73; 95% CI, 0.54-0.99, P = .045). The intervention effect was consistent across all prespecified subgroups. The comparison of secondary outcomes did not demonstrate significant results.ConclusionAmong patients with persistent AF, linear ablation combined with EIVOM in addition to PVI significantly improved freedom from atrial arrhythmias within 12 months compared with PVI alone.Trial RegistrationClinicalTrials.gov Identifier: NCT04497376

Effect of identification and treatment of early pulmonary vein re-connection on clinical results of atrial fibrillation ablation

Dissociated pulmonary vein rhythm may predict the acute pulmonary vein reconnection post-isolation in patients with paroxysmal atrial fibrillation.

Early detection of pulmonary vein reconnection after isolation in patients with paroxysmal atrial fibrillation: a comparison of ATP-induction and reassessment at 30 minutes postisolation.

Intraprocedural Endpoints To Predict Durable Pulmonary Vein Isolation: A Randomized Trial Of Four Post-Ablation Techniques

Pulmonary Vein Isolation with Optimized Linear Ablation Vs Pulmonary Vein Isolation Alone for Persistent AF

A single pulmonary vein as electrophysiological substrate of paroxysmal atrial fibrillation.

Efficiency and Safety of Electrical Isolation PV with Saline Irrigated Radiofrequency Catheter Ablation in Treating Patients with Paroxysmal AF

Incidence of Pulmonary Vein Conduction Recovery in Patients Without Clinical Recurrence after Ablation of Paroxysmal Atrial Fibrillation: Mechanistic Implications.

GW26-e4813 Impact of Anatomically-guided Ganglionated Plexus Ablation on Electrical Firing from Isolated Pulmonary Veins

Efficacy of Ablation Index-Guided Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation.

Treatment of Long-Standing Persistent Atrial Fibrillation by Linear Ablation

Inducibility and ablation of atrial fibrillation from non-pulmonary vein foci in patients with paroxysmal atrial fibrillation

Circumferential Pulmonary Vein Isolation With vs Without Additional Low-Voltage-Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation

Pulmonary Vein Tachycardia after Pulmonary Vein Isolation in Patients with Atrial Fibrillation

Achievement of Pulmonary Vein Isolation in Patients Undergoing Circumferential Pulmonary Vein Ablation: A Randomized Comparison Between Two Different Isolation Approaches

Marked Suppression of Pulmonary Vein Firing after Circumferential Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation: is Pulmonary Vein Firing an Epiphenomenon?

Clinical Evaluation of Circumferential Ultrasound Ablation of Pulmonary Veins for Patients with Paroxysmal Atrial Fibrillation

Irrigated-tip Catheter Ablation for Electrical Isolation of Atrium-Pulmonary Vein to Treat Paroxysmal Atrial Fibrillation

Non-pulmonary vein foci induced before and after pulmonary vein isolation in patients undergoing ablation therapy for paroxysmal atrial fibrillation: incidence and clinical outcome

Ultrasound Ablation of Pulmonary Veins for Treatment of Paroxysmal Atrial Fibrillation

Comparison of Long-Term Clinical Outcomes Between Segmental and Circumferential Pulmonary Vein Isolation in Patients Undergoing Repeat Atrial Fibrillation Ablation.